Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial.

Zelniker TA, Bonaca MP, Furtado R, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.

Circulation. 2020 Jan 27. doi: 10.1161/CIRCULATIONAHA.119.044183. [Epub ahead of print]

PMID:
31983236
2.

Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study.

Ramotowski B, Gurbel PA, Tantry U, Bracha JS, Karaźniewicz-Łada M, Lewandowski Z, Budaj A.

Thromb Haemost. 2020 Jan 15. doi: 10.1055/s-0039-3402758. [Epub ahead of print]

PMID:
31940672
3.

ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial.

Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, Budaj A, Cornel JH, Himmelmann A, James SK, Siegbahn A, Storey RF, Kontny F, Aukrust P, Wallentin L; PLATO Investigators.

Atherosclerosis. 2020 Jan;293:35-41. doi: 10.1016/j.atherosclerosis.2019.11.031. Epub 2019 Nov 29.

PMID:
31835039
4.

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.

Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP.

Eur Heart J. 2019 Dec 7. pii: ehz821. doi: 10.1093/eurheartj/ehz821. [Epub ahead of print]

PMID:
31811715
5.

Assessment of quality of care of patients with ST-segment elevation myocardial infarction.

Hudzik B, Budaj A, Gierlotka M, Witkowski A, Wojakowski W, Zdrojewski T, Gil R, Legutko J, Bartuś S, Buszman P, Dudek D, Gąsior M.

Eur Heart J Acute Cardiovasc Care. 2019 Nov 25:2048872619882360. doi: 10.1177/2048872619882360. [Epub ahead of print]

PMID:
31762288
6.

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.

Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG.

Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005858. doi: 10.1161/CIRCOUTCOMES.119.005858. Epub 2019 Nov 11.

PMID:
31707826
7.

Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.

Vora AN, Alexander JH, Wojdyla DM, Aronson R, Granger CB, Darius H, Windecker S, Mehran R, Averkov O, Budaj A, Kong DF, Kobalava Z, Mehta RH, Mirza Z, Guimaraes PO, Parkhomenko A, Quadros A, Thiele H, Goodman SG, Lopes RD.

Circulation. 2019 Dec 3;140(23):1960-1963. doi: 10.1161/CIRCULATIONAHA.119.043754. Epub 2019 Sep 25. No abstract available.

PMID:
31553201
8.

Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Åkerblom A, Wojdyla D, Steg PG, Wallentin L, James SK, Budaj A, Katus HA, Himmelmann A, Huber K, Siegbahn A, Storey RF, Becker RC; PLATO Investigators.

J Thromb Thrombolysis. 2019 Nov;48(4):563-569. doi: 10.1007/s11239-019-01938-2.

9.

Smoking and cardiovascular diseases: paradox greater than expected?

Ramotowski B, Gurbel PA, Tantry U, Budaj A.

Pol Arch Intern Med. 2019 Oct 30;129(10):700-706. doi: 10.20452/pamw.14931. Epub 2019 Aug 16.

10.

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators.

Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;:. Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.

11.

Improvement of left ventricular function after percutaneous coronary intervention in patients with stable coronary artery disease and preserved ejection fraction: Impact of diabetes mellitus.

Sikora-Frac M, Zaborska B, Maciejewski P, Budaj A, Bednarz B.

Cardiol J. 2019 Jul 1. doi: 10.5603/CJ.a2019.0066. [Epub ahead of print]

12.

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.

Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):200-206. doi: 10.1093/ehjcvp/pvz020.

13.

Significant left ventricular outflow tract obstruction observed during postexercise verticalization in a symptomatic patient with hypertrophic cardiomyopathy.

Smarż K, Zaborska B, Pilichowska-Paszkiet E, Sikora-Frąc M, Budaj A.

Kardiol Pol. 2019 Jun 25;77(6):655-656. doi: 10.33963/KP.14860. Epub 2019 Jun 6. No abstract available.

14.

Increased coagulation factor XIII activity but not genetic variants of coagulation factors is associated with myocardial infarction in young patients.

Ambroziak M, Kuryłowicz A, Budaj A.

J Thromb Thrombolysis. 2019 Oct;48(3):519-527. doi: 10.1007/s11239-019-01856-3.

15.

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.

Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators.

N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.

16.

Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial.

Franchi F, James SK, Ghukasyan Lakic T, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Storey RF, Himmelmann A, Wallentin L, Angiolillo DJ; PLATO Investigators.

J Am Heart Assoc. 2019 Mar 19;8(6):e011139. doi: 10.1161/JAHA.118.011139.

17.

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.

Held C, White HD, Stewart RAH, Davies R, Sampson S, Chiswell K, Silverstein A, Lopes RD, Heldestad U, Budaj A, Mahaffey KW, Wallentin L; STABILITY Investigators.

Am Heart J. 2019 Feb;208:65-73. doi: 10.1016/j.ahj.2018.10.010. Epub 2018 Nov 7.

18.

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.

Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Diaz R, Van de Werf F, Corbalán R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS.

J Am Heart Assoc. 2018 Nov 20;7(22):e009260. doi: 10.1161/JAHA.118.009260.

19.

Exercise left ventricular outflow tract obstruction as a cause of exercise intolerance: combined stress echocardiography and cardiopulmonary exercise testing.

Smarż K, Zaborska B, Jaxa-Chamiec T, Budaj A.

Kardiol Pol. 2018;76(10):1492. doi: 10.5603/KP.2018.0209. No abstract available.

20.

A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection.

Lewandowski P, Baran J, Maciejewski P, Budaj A.

Vasa. 2019 Mar;48(2):181-184. doi: 10.1024/0301-1526/a000751. Epub 2018 Oct 16.

21.

Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future.

Kotecha D, Bax JJ, Carrera C, Casadei B, Merkely B, Anker SD, Vardas PE, Kearney PP, Roffi M, Ros M, Vahanian A, Weidinger F, Beeri R, Budaj A, Calabrò P, Czerwińska-Jelonkiewicz K, D'Ascenzi F, De Potter T, Fox KF, Hartikainen J, McAdam B, Milicic D, Pasquet AA, Sionis A, Sohaib SMA, Tsioufis C, Verhorst PMJ, Kirchhof P; ESC Scientific Document Group ; 2016 ESC Education Conference .

Eur Heart J. 2019 Jun 1;40(21):1728-1738. doi: 10.1093/eurheartj/ehy058.

PMID:
30226525
22.

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators.

N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26.

23.

Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events).

Worme MD, Tan MK, Armstrong DWJ, Yan AT, Tan NS, Brieger D, Budaj A, Gore JM, López-Sendón J, Van de Werf F, Steg PG, Fox KAA, Goodman SG, Udell JA.

Am J Cardiol. 2018 Sep 15;122(6):944-951. doi: 10.1016/j.amjcard.2018.06.001. Epub 2018 Jun 21.

PMID:
30115426
24.

ESR2 gene G1730A variant is associated with triglycerides level and myocardial infarction in young men but not in women.

Ambroziak M, Kuryłowicz A, Roszkowska-Gancarz M, Budaj A.

Gene. 2018 Nov 30;677:83-88. doi: 10.1016/j.gene.2018.07.048. Epub 2018 Jul 20.

PMID:
30036658
25.

Echocardiographic predictors of exercise intolerance in patients with heart failure with severely reduced ejection fraction.

Zaborska B, Smarż K, Makowska E, Czepiel A, Świątkowski M, Jaxa-Chamiec T, Budaj A.

Medicine (Baltimore). 2018 Jul;97(28):e11523. doi: 10.1097/MD.0000000000011523.

26.

Response to "Acetazolamide and Cardiac Failure".

Imiela T, Budaj A.

Clin Drug Investig. 2018 Jul;38(7):651. doi: 10.1007/s40261-018-0654-0. No abstract available.

27.

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.

Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue ML.

JAMA Cardiol. 2018 Jun 1;3(6):473-480. doi: 10.1001/jamacardio.2018.0653.

28.

Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest.

Sarak B, Goodman SG, Brieger D, Gale CP, Tan NS, Budaj A, Wong GC, Huynh T, Tan MK, Udell JA, Bagai A, Fox KAA, Yan AT; Global Registry of Acute Coronary Events (GRACE) Investigators and the Canadian Acute Coronary Syndromes I Investigators.

Am J Cardiol. 2018 Feb 1;121(3):294-300. doi: 10.1016/j.amjcard.2017.10.030. Epub 2017 Nov 3.

PMID:
29197473
29.

Adiponectin gene variants and decreased adiponectin plasma levels are associated with the risk of myocardial infarction in young age.

Ambroziak M, Kolanowska M, Bartoszewicz Z, Budaj A.

Gene. 2018 Feb 5;642:498-504. doi: 10.1016/j.gene.2017.11.064. Epub 2017 Nov 28.

PMID:
29196254
30.

Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.

Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, Koenig W, Siegbahn A, Steg PG, Soffer J, Weaver WD, Östlund O, Wallentin L; STABILITY Investigators.

J Am Heart Assoc. 2017 Oct 24;6(10). pii: e005077. doi: 10.1161/JAHA.116.005077.

31.

Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study.

Imiela T, Budaj A.

Clin Drug Investig. 2017 Dec;37(12):1175-1181. doi: 10.1007/s40261-017-0577-1.

32.

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.

Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagström E, Held C, Koenig W, Östlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, März W, Wallentin L.

J Am Coll Cardiol. 2017 Aug 15;70(7):813-826. doi: 10.1016/j.jacc.2017.06.030.

33.

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.

Vedin O, Hagström E, Östlund O, Avezum A, Budaj A, Flather MD, Harrington RA, Koenig W, Soffer J, Siegbahn A, Steg PG, Stewart RAH, Wallentin L, White HD, Held C; STABILITY Investigators.

Int J Cardiol. 2017 Oct 15;245:271-276. doi: 10.1016/j.ijcard.2017.07.036. Epub 2017 Jul 17.

PMID:
28735759
34.

Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.

Ramotowski B, Żuk A, Budaj A.

Kardiol Pol. 2017;75(6):614. doi: 10.5603/KP.2017.0104. No abstract available.

35.

Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.

Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Cannon CP, Becker RC, James SK, Katus HA, Lopes RD, Sorbets E, Wallentin L, Steg PG.

Am Heart J. 2017 Apr;186:91-99. doi: 10.1016/j.ahj.2017.01.010. Epub 2017 Jan 26.

PMID:
28454837
36.

Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.

Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER 3rd, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L; STABILITY Investigators.

Clin Chem. 2017 Jan;63(1):325-333. doi: 10.1373/clinchem.2016.260570. Epub 2016 Nov 3.

37.

A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score.

Mehta SR, Eikelboom JW, Rao-Melacini P, Weitz JI, Anand SS, Pare G, Budaj A, Pogue J, Fox KA, Yusuf S.

Can J Cardiol. 2016 Nov;32(11):1332-1339. doi: 10.1016/j.cjca.2016.01.029. Epub 2016 Feb 2.

PMID:
27062239
38.

Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.

Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Špinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS.

JAMA Cardiol. 2016 Jul 1;1(4):425-32. doi: 10.1001/jamacardio.2016.1017.

39.

Right ventricular systolic function as a marker of prognosis after ST-elevation inferior myocardial infarction 5-year follow-up.

Smarz K, Zaborska B, Jaxa-Chamiec T, Tysarowski M, Budaj A.

Int J Cardiol. 2016 Oct 15;221:549-53. doi: 10.1016/j.ijcard.2016.07.088. Epub 2016 Jul 5.

PMID:
27414738
40.

Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events.

Arbel Y, FitzGerald G, Yan AT, Tan MK, Fox KAA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Budaj A, Lopez-Sendon J, Avezum A, Granger CB, Goodman SG.

Int J Cardiol. 2016 Sep 1;218:291-297. doi: 10.1016/j.ijcard.2016.05.064. Epub 2016 May 15. No abstract available.

PMID:
27240154
41.

Clopidogrel allergy successfully treated with corticosteroids without clopidogrel withdrawal.

Ramotowski B, Budaj A.

Kardiol Pol. 2016;74(5):489. doi: 10.5603/KP.2016.0066. No abstract available.

42.

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.

O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA; LATITUDE-TIMI 60 Investigators.

JAMA. 2016 Apr 19;315(15):1591-9. doi: 10.1001/jama.2016.3609.

PMID:
27043082
43.

Bleeding and Quality of Life.

Budaj A.

J Am Coll Cardiol. 2016 Jan 5;67(1):66-8. doi: 10.1016/j.jacc.2015.10.035. No abstract available.

44.

Tooth loss is independently associated with poor outcomes in stable coronary heart disease.

Vedin O, Hagström E, Budaj A, Denchev S, Harrington RA, Koenig W, Soffer J, Sritara P, Stebbins A, Stewart RH, Swart HP, Viigimaa M, Vinereanu D, Wallentin L, White HD, Held C; STABILITY Investigators.

Eur J Prev Cardiol. 2016 May;23(8):839-46. doi: 10.1177/2047487315621978. Epub 2015 Dec 16.

PMID:
26672609
45.

Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.

Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, López-Sendón J, Diaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS.

Eur Heart J. 2016 Apr 7;37(14):1133-42. doi: 10.1093/eurheartj/ehv531. Epub 2015 Oct 21.

PMID:
26491109
46.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.

N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

47.

Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up.

Alnasser SM, Huang W, Gore JM, Steg PG, Eagle KA, Anderson FA Jr, Fox KA, Gurfinkel E, Brieger D, Klein W, van de Werf F, Avezum Á, Montalescot G, Gulba DC, Budaj A, Lopez-Sendon J, Granger CB, Kennelly BM, Goldberg RJ, Fleming E, Goodman SG; GRACE Investigators.

Am J Med. 2015 Jul;128(7):766-75. doi: 10.1016/j.amjmed.2014.12.007. Epub 2014 Dec 29.

PMID:
25554379
48.

High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events.

Singh SM, FitzGerald G, Yan AT, Brieger D, Fox KA, López-Sendón J, Yan RT, Eagle KA, Steg PG, Budaj A, Goodman SG.

Eur Heart J. 2015 Apr 21;36(16):976-83. doi: 10.1093/eurheartj/ehu357. Epub 2014 Sep 8.

PMID:
25205530
49.

A rare case of tricuspid valve mass in a patient with left and right ventricular dysfunction and severe ischaemic mitral regurgitation.

Zaborska B, Pilichowska-Paszkiet E, Czempik E, Budaj A.

Kardiol Pol. 2014;72(6):552. doi: 10.5603/KP.2014.0120. No abstract available.

50.

Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.

Akerblom A, Eriksson N, Wallentin L, Siegbahn A, Barratt BJ, Becker RC, Budaj A, Himmelmann A, Husted S, Storey RF, Johansson A, James SK; PLATO Investigators.

Am Heart J. 2014 Jul;168(1):96-102.e2. doi: 10.1016/j.ahj.2014.03.010. Epub 2014 Apr 4.

PMID:
24952865

Supplemental Content

Support Center